Antibody drug conjugates (ADCs) are the fastest growing class of oncologic agents; however, several ADCs have pneumonitis incidence higher than other agents notorious for pulmonary complications, including immune checkpoint inhibitors. ADCs have mechanistic properties that limit payload toxicities by selective delivery to tumor cells but may generate immunogenic reactions systemically. As ADCs are increasingly approved and utilized for metastatic lung cancer, pulmonologists need to be aware of this potentially devasting complication. In this session, the presenters will discuss the presentation, diagnostic workup, and management of pneumonitis related to ADCs, including current gaps in knowledge and expert opinion on best practices.
Panelists: Jay Leb
Jennifer Possick, Pulmonary
Margaret Gatti-Mays, Oncology
Presenters: Kathleen Capaccione, Maida Hafiz, Kevin Ho